Table of Contents Table of Contents
Previous Page  296 / 812 Next Page
Information
Show Menu
Previous Page 296 / 812 Next Page
Page Background

S292

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

Results

Erythrocyte GPx activity was significantly lower in

patients with schizophrenia than in controls. Male patients had

significantly lower GPx activity in comparison with those in

female ones. Heredity negative patients showed significantly lower

enzyme activity compared to control values. Significantly lower

GPx activitywas obtained independently of the onset of the disease.

The patient group having more than one psychotic episode also

showed significantly lower GPx activity compared to the control

group. The disease duration of more than 1 year caused a signifi-

cant decrease in enzyme activity. There was a significant difference

in GPx activity between patients with different PANSS scores. In

patients treatedwith second generation antipsychotics and in those

treated with both first and second generation antipsychotics, GPx

activity was significantly lower than in controls.

Conclusion

This study shows that the low erythrocyte GPx activ-

ity in schizophrenics depends on patient gender, the number of

episodes, disease duration and drug treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.625

EW508

Exploration of the link between

clinical judgments and subjective

perceptions of clinical change in

patients treated for schizophrenia

S. Egger

, S. Vetter , S. Prinz , G. Weniger , M. Müller

University hospital for psychiatry, ZIP- Rheinau, Zurich, Switzerland

Corresponding author.

Introduction

Subjective perceptions of clinical change in patients

with schizophrenia are often not congruent to the objective evi-

dence of the same, especially since a lack of insight is part of

the symptomatology. However, the exploration of the relationship

between clinical judgments from mental health experts and the

patients’ perception of symptom change is fairly understudied.

Aims and objectives

This study aimed to investigate the perfor-

mance of the Positive and Negative Syndrome Scale (PANSS) as a

tool for clinical outcome monitoring in schizophrenia in concord-

ance with the change of self-reported psychopathology assessed

with the Frankfurt Complaint Questionnaire (FCQ) in patients with

a schizophrenia.

Methods

A consecutive sample of patients admitted to a Swiss

psychiatric hospital for schizophrenia was assessed with the FCQ

at admission and discharge. The PANSSwas rated by the responsible

clinicians at admission and discharge. Complete data of admission

and discharge were available from approximately 60 cases. Reli-

able change index (RCI) was calculated to determine a clinically

meaningful change based on the PANSS scores. Logistic regression

models were conducted to explore the link between RCI levels and

the change of self-reported perceptions of psychopathology.

Results and xonclusions

Our study found no relationship between

the change of PANSS and FCQ from admission to discharge in a

sample of patients treated for schizophrenia. Therefore, our find-

ings provide evidence for a large discrepancy between the observed

clinical severity and the subjective perception of symptoms in indi-

viduals with schizophrenia.

Keywords

Positive and Negative Syndrome Scale; Frankfurt

Complain Questionnaire; Schizophrenia; Outcome monitoring;

Subjective perception

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.626

EW509

Ethnic difference in medication

adherence and compounding factors

in treatment of early stages of

psychotic disorders

T. Elanjithara

1 ,

, T. Winton-Brown

2

1

Durham, United Kingdom

2

Kings College London, Psychosis Studies, London, United Kingdom

Corresponding author.

Introduction

Studies shown ethnic difference in illness-

awareness, medication acceptance, difference in types and doses

of medication prescribed in certain ethnic groups in treatment of

psychosis.

Objectives

To study antipsychotic adherence patterns in ethnic

groups and to study factors influencing.

Aims

To analyse any difference in the adherence patterns

between ethnic groups and identify factors mediating any effects.

Methods

One hundred and twenty-seven consecutive patients

presenting to early-intervention service in South-London included

in naturalistic study. Sample binarised into Caucasian (white

British, other white background,

n

= 36, 28%) and combined Black

and Minority Ethnic (BME,

n

= 91, 72%) groups. Medication adher-

ence studied using self and carer reports, looking for percentage of

times taking medications, any gaps in treatment (atleast 1 month).

Range of demographic and clinical parameters collected including

use of substances and medications side-effects.

Results

Patients with treatment gap (atleast 1 month) had simi-

lar demographic and clinical characteristics with the rest, except

the former were more likely to have reported extra-pyramidal

(EPSE) (Pearson

2

= 5.6, df = 1,

P

= 0.02), and to be BME rather

than Caucasian (BME

n

= 57, 64%, Caucasian

n

= 16. 44%, Pearson

2

= 4.5, df = 1,

P

= 0.05). These variables were further entered in

stepped multivariate regression, only the effect of EPSE remained

significant, with odds ratio 8,

P

= 0.05. There was no difference in

Chlorpromazine equivalent dose between ethnic groups (Caucasian

mean-dose 156 mg, BME 138 mg,

t

= 1.2,

P

= 0.2). Also there was no

significant difference in types of antipsychotics prescribed (

2

= 4,

P

= 0.1, df = 2) between the ethnic groups.

Conclusions

Ethnic difference in antipsychotic adherence may

also be influenced by sensitivity to certain side effects.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.627

EW510

Anti-DNA antibodies in the blood of

patients with schizophrenia possess

DNA-hydrolyzing activity

E. Ermakov

1 ,

, L. Smirnova

1

, L. Sinyanskii

2

, D. Dobrygina

2

,

A. Semke

3

, G. Nevinsky

4

, V. Buneva

4

, S. Ivanova

1

1

Mental health research institute, laboratory of molecular genetics

and biochemistry, Tomsk, Russia

2

Siberian state medical universitu, department of neurology and

neurosurgery, Tomsk, Russia

3

Mental health research institute, department endogenous disorders,

Tomsk, Russia

4

Institute of chemical biology and fundamental medicine, laboratory

repair enzymes, Novosibirsk, Russia

Corresponding author.

Introduction

Autoantibodies (Abs) to different neuronal recep-

tors and DNA were detected in the blood of patients with